<PAGE> 1
February 12, 1999
VIA FACSIMILE AND EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Mail Stop 3-9
Washington, D.C. 20549
Attn: Jeffrey P. Riedler, Assistant Director
CELTRIX PHARMACEUTICALS, INC.
CIK: 0000871395
COMMISSION FILE NO. 333-61873: APPLICATION FOR WITHDRAWAL
Ladies and Gentlemen:
Pursuant to Rule 477(a) promulgated under the Securities Act of 1933, as
amended, the undersigned registrant (the "Registrant") hereby applies for an
Order granting the immediate withdrawal of its Registration Statement on Form
S-3, together with all exhibits and amendments thereto, Commission File No.
333-61873 (collectively, the "Registration Statement"). The Registration
Statement was originally filed with the Commission on August 20, 1998.
Pursuant to the Registration Statement, the Registrant proposed to register
on behalf of specified selling stockholders an aggregate of 10,075,000 shares of
its Common Stock, $0.01 par value per share (the "Shares"), for resale to the
public, at a proposed maximum offering price per Share of $1.90625, with a
proposed maximum offering price of $19,205,468.75. No securities have been sold
under the Registration Statement and the Registrant does not believe that
keeping the Registration Statement on file would be in the best interests of the
Registrant or the selling stockholders.
Accordingly, we hereby request that an Order granting the withdrawal of the
Registration Statement be issued by the Commission as soon as possible.
<PAGE> 2
If you have any questions regarding the foregoing application for
withdrawal, please contact Edmund Ruffin or Francie Johnston at Venture Law
Group, legal counsel to the Registrant in connection with the Registration
Statement, at (650) 854-4488.
Sincerely,
CELTRIX PHARMACEUTICALS, INC.
/s/ Andreas Sommer
-------------------------------------
Andreas Sommer
President and Chief Executive Officer
